Entero Therapeutics, Inc. Quarterly Interest Expense in USD from Q3 2015 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Entero Therapeutics, Inc. quarterly/annual Interest Expense history and growth rate from Q3 2015 to Q1 2024.
  • Entero Therapeutics, Inc. Interest Expense for the quarter ending March 31, 2024 was $66.2K, a 637% increase year-over-year.
  • Entero Therapeutics, Inc. Interest Expense for the twelve months ending March 31, 2024 was $79.7K, a 314% increase year-over-year.
  • Entero Therapeutics, Inc. annual Interest Expense for 2023 was $22.5K, a 41.5% increase from 2022.
  • Entero Therapeutics, Inc. annual Interest Expense for 2022 was $15.9K, a 41.3% increase from 2021.
  • Entero Therapeutics, Inc. annual Interest Expense for 2021 was $11.2K, a 99.8% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $79.7K $66.2K +$57.2K +637% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $22.5K $7.05K +$855 +13.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 $21.6K $1.25K +$387 +44.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $21.2K $5.18K +$1.96K +60.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $19.3K $8.99K +$3.38K +60.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $15.9K $6.19K +$3.8K +159% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 $12.1K $863 +$121 +16.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $12K $3.22K +$264 +8.94% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $11.7K $5.61K +$461 +8.96% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $11.2K $2.4K +$198 +9.01% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 $11K $742 -$1.2M -99.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.21M $2.95K -$2.3M -99.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $3.51M $5.14K -$2.33M -99.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-23
Q4 2020 $5.84M $2.2K -$154K -98.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $5.99M $1.2M +$1.09M +990% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-11-16
Q2 2020 $4.9M $2.3M +$2.19M +1981% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $2.71M $2.33M +$2.28M +3985% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q4 2019 $434K $156K +$154K +10809% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $280K $110K +$105K +1861% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $175K $111K +$64.5K +140% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $110K $57.1K +$8.48K +17.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $102K $1.43K -$177K -99.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 $279K $5.63K -$402K -98.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $682K $46.2K -$241K -83.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $923K $48.6K +$47.8K +5465% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $875K $179K -$3.93M -95.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-04-01
Q3 2017 $4.81M $408K -$317K -43.7% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $5.12M $287K -$101K -26% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $5.22M $874 -$713K -99.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 $5.94M $4.11M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 $725K +$204K +39.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 $388K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $714K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q3 2015 $521K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.